ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Kemas kini terakhir: 2 hari lalu, 7:42AM

189.28

-1.47 (-0.77%)

Penutupan Terdahulu 190.75
Buka 191.15
Jumlah Dagangan 3,706,217
Purata Dagangan (3B) 7,500,001
Modal Pasaran 334,344,192,000
Harga / Pendapatan (P/E TTM) 80.54
Harga / Pendapatan (P/E Ke hadapan) 15.70
Harga / Jualan (P/S) 5.89
Harga / Buku (P/B) 237.28
Julat 52 Minggu
163.63 (-13%) — 218.66 (15%)
Tarikh Pendapatan 31 Jul 2025
Hasil Dividen (DY TTM) 3.37%
Margin Keuntungan 7.31%
Margin Operasi (TTM) 30.43%
EPS Cair (TTM) 2.35
Pertumbuhan Hasil Suku Tahunan (YOY) 8.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -6.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 4,789.60%
Nisbah Semasa (MRQ) 0.760
Aliran Tunai Operasi (OCF TTM) 16.40 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 16.94 B
Pulangan Atas Aset (ROA TTM) 8.34%
Pulangan Atas Ekuiti (ROE TTM) 88.40%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menurun Bercampur
Drug Manufacturers - General (Global) Menurun Bercampur
Stok AbbVie Inc. Menurun Menaik

AISkor Stockmoo

3.0
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 5.0
Osilator Teknikal 4.0
Purata 3.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ABBV 334 B 3.37% 80.54 237.28
JNJ 375 B 2.38% 17.35 4.81
PFE 144 B 5.00% 18.39 1.58
BMY 95 B 3.88% 17.51 5.57
GSK 78 B 2.03% 18.27 3.97
LLY 701 B 0.53% 63.68 44.16

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.10%
% Dimiliki oleh Institusi 74.40%
227.90227.90195.20195.20162.50162.50129.80129.8097.1097.10Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
163.63 (-13%) — 218.66 (15%)
Julat Harga Sasaran
194.00 (2%) — 250.00 (32%)
Tinggi 250.00 (Morgan Stanley, 32.08%) Beli
Median 207.50 (9.63%)
Rendah 194.00 (Goldman Sachs, 2.49%) Pegang
Purata 213.33 (12.71%)
Jumlah 4 Beli, 2 Pegang
Harga Purata @ Panggilan 184.18
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Citigroup 14 May 2025 205.00 (8.31%) Pegang 177.44
Guggenheim 29 Apr 2025 216.00 (14.12%) Beli 193.51
17 Apr 2025 214.00 (13.06%) Beli 172.99
Evercore ISI Group 28 Apr 2025 205.00 (8.31%) Beli 192.34
Morgan Stanley 28 Apr 2025 250.00 (32.08%) Beli 192.34
09 Apr 2025 241.00 (27.32%) Beli 179.84
Cantor Fitzgerald 22 Apr 2025 210.00 (10.95%) Beli 173.78
Goldman Sachs 08 Apr 2025 194.00 (2.49%) Pegang 175.67

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
30 Jun 2025 Pengumuman AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
30 Jun 2025 Pengumuman AbbVie to Host Second-Quarter 2025 Earnings Conference Call
30 Jun 2025 Pengumuman U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
20 Jun 2025 Pengumuman AbbVie Declares Quarterly Dividend
18 Jun 2025 Pengumuman AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
17 Jun 2025 CNBC Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
16 Jun 2025 Pengumuman AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
11 Jun 2025 Pengumuman U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
03 Jun 2025 Pengumuman AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
03 Jun 2025 Pengumuman AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
30 May 2025 Pengumuman AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
14 May 2025 Pengumuman U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
14 May 2025 Pengumuman AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
06 May 2025 Pengumuman AbbVie to Present at the Bank of America Securities Healthcare Conference
05 May 2025 CNBC Trump signs order to boost domestic drug manufacturing as pharma tariffs loom
01 May 2025 Pengumuman BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
29 Apr 2025 Pengumuman RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
25 Apr 2025 Pengumuman AbbVie Reports First-Quarter 2025 Financial Results
24 Apr 2025 Pengumuman AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
08 Apr 2025 Pengumuman AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
Papar semua
Hasil Dividen (DY TTM) 3.37%
Purata Hasil Dividen 5T 3.81%
Nisbah Pembayaran 268.80%
Jangkaan Pembayaran Dividen Seterusnya Nov 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Tunai
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Tunai
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Tunai
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Tunai
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Tunai
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Tunai
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Tunai
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Tunai
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Tunai
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Tunai
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Tunai
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Tunai
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Tunai
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Tunai
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Tunai
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Tunai
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Tunai
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Tunai
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Tunai
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Tunai
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Tunai
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Tunai
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Tunai
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Tunai
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Tunai
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Tunai
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Tunai
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Tunai
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Tunai
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Tunai
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Tunai
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Tunai
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Tunai
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Tunai
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Tunai
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Tunai
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Tunai
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Tunai
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Tunai
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Tunai
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Tunai
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Tunai
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Tunai
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Tunai
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Tunai
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Tunai
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Tunai
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Tunai
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Tunai
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 3.28 2 1.73
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Papar semua
193.68193.68189.33189.33184.99184.99180.64180.64176.30176.30Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
1.0001.0000.5000.5000.0000.000-0.500-0.500-1.000-1.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda